8-K
filed October 3, 2025, 7:59 PM ET
ticker OVID
CIK 0001636651
other material
confidence high
sentiment positive
materiality 0.85
Ovid reports positive Phase 1 OV329 results and raises $175M in PIPE financing
Ovid Therapeutics Inc.
- OV329 Phase 1: 53% inhibition increase on LICI biomarker (p=0.0001) at 5mg, exceeding vigabatrin (~35%); mild AEs only.
- No ophthalmic changes observed; plan Phase 2a in drug-resistant focal onset seizures Q2 2026.
- PIPE financing of up to $175.1M (initial $80.8M) from sale of Series B Preferred and warrants at $1.40/share.
- Warrants exercisable after stockholder approval; proceeds for R&D and working capital; closing Oct 6, 2025.
- KCC2 program updates: OV350 topline PK data Q4 2025; OV4071 IND filing Q1 2026.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Ovid Therapeutics Inc. issued to purchase 38,481,325 shares of Common Stock of warrant to the Investors (including the Chief Executive Officer) for $1,400.00 per Security.
- Security
- warrant
- Shares
- to purchase 38,481,325 shares of Common Stock
- Purchaser
- the Investors (including the Chief Executive Officer)
- Consideration
- $1,400.00 per Security
Exact text from the filing
purchase) and a Series B Warrant to purchase 500 shares of Common Stock and/or Pre-Funded Warrants (together, a “Security”). The Securities will be sold at a purchase price of $1,400.00 per Security to the Investors, which includes the Company’s Chief Executive Officer. The Warrants will each have an exercise price of $1.40 per share. The PIPE financing is
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Ovid Therapeutics Inc. issued 57,722 shares of preferred stock to the Investors (including the Chief Executive Officer) for $1,400.00 per Security.
- Security
- preferred stock
- Shares
- 57,722 shares
- Purchaser
- the Investors (including the Chief Executive Officer)
- Consideration
- $1,400.00 per Security
Exact text from the filing
purchase) and a Series B Warrant to purchase 500 shares of Common Stock and/or Pre-Funded Warrants (together, a “Security”). The Securities will be sold at a purchase price of $1,400.00 per Security to the Investors, which includes the Company’s Chief Executive Officer. The Warrants will each have an exercise price of $1.40 per share. The PIPE financing is
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Ovid Therapeutics Inc. issued to purchase 28,861,000 shares of Common Stock of warrant to the Investors (including the Chief Executive Officer) for $1,400.00 per Security.
- Security
- warrant
- Shares
- to purchase 28,861,000 shares of Common Stock
- Purchaser
- the Investors (including the Chief Executive Officer)
- Consideration
- $1,400.00 per Security
Exact text from the filing
purchase) and a Series B Warrant to purchase 500 shares of Common Stock and/or Pre-Funded Warrants (together, a “Security”). The Securities will be sold at a purchase price of $1,400.00 per Security to the Investors, which includes the Company’s Chief Executive Officer. The Warrants will each have an exercise price of $1.40 per share. The PIPE financing is
View on SEC.gov
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
Ovid Therapeutics Inc.: Filed Certificate of Designation establishing Series B Convertible Preferred Stock designating 57,722 shares of preferred stock (effective 2025-10-03).
- Change
- charter amendment
- Effective
- 2025-10-03
Exact text from the filing
On October 3, 2025, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 57,722 shares of its authorized and unissued preferred stock as Series B Preferred Stock.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.